IPN, Delhi, India. Open 10-6pm

+91 9891296838 / 9811747774

decitabine and cedazuridine tablets

decitabine and cedazuridine tablets,
for oral use Initial U.S. Approval: 2020

Inqovi (decitabine and cedazuridine) is a medication used for the treatment of adults with myelodysplastic syndromes (MDS), including chronic myelomonocytic leukemia (CMML).

Facts about decitabine and cedazuridine tablets

Disease Indications-Leukemia
Manufacturer-Astex Pharmaceuticals
Medicine Approved By-Food and Drug Administration (FDA), Health Canada
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “decitabine and cedazuridine tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

Contact Info

Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398



Query For decitabine and cedazuridine tablets

Approved accessible "decitabine and cedazuridine tablets"

The US FDA approved Decitabine and Cedazuridine under the trade name INQOVI for treating adults with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia, a kind of blood cancer. Dosage form: The drug is available as a tablet to be taken once a day on Days 1 through 5 of each 28-day cycle. The drug can cause serious and life-threatening bone marrow suppression. Common adverse effects caused by the drug are low cell counts, tiredness, constipation, bleeding, muscle pain, joint pain, nausea, shortness of breath, diarrhea, rash, dizziness, febrile neutropenia, swelling of arms or legs, and headache. The drug's safety and efficacy are evidenced by two clinical trials on 213 patients with MDS or chronic myelomonocytic leukemia.

How can 1 go about obtaining decitabine and cedazuridine tablets?

To access decitabine and cedazuridine tablets sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN's Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj)

INQOVI (decitabine and cedazuridine) tablets, for oral use Initial U.S. Approval: 2020

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa

Indian Pharma Network
60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398